Orphan-Drug-Designation Biopharma (1,910 companies)
188 Companies
Access all companiesSpotfolio tracks over one million companies in technology industries.
There are 188 companies in the field of Biopharma on spotfolio that produce or deliver products, that utilize or research technologies or that are otherwise engaged in topics such as Clinical, Drug, Patients, Treatment, Therapies, FDA, Therapeutics, Phase, Orphan-Drug-Designation .
Start-ups (19)
Early-stage companies (49)
Established companies (111)
The majority of these companies is located in the following countries.
United States (113)
United Kingdom (8)
Australia (6)
Canada (6)
Example Companies
Find companies in your areaBexion Pharmaceuticals
Access
- Technologies
- Core data such as location, employees, revenues
- Similar and peer companies
- and more
Web Quotes
Milestones - Media & Press - Contact Bexion Pharmaceuticals Receives Orphan Drug Designation for Saposin C, the Active Ingredient in BXQ-350 for Glioblastoma ...
Glioblastoma Multiforme from FDA Bexion Pharmaceuticals Receives Orphan Drug Designation for Saposin C, the Active Ingredient in BXQ-350 for Glioblastoma Multiforme ...
U.S. Food and Drug Administration (FDA) has granted the company Orphan Drug designation for Saposin C, active ingredient in its proprietary drug BXQ-350 ...
designation have become sought after assets.” About Orphan Drug Designation Orphan Drug designation is a status assigned to a medicine intended for use ...
use in rare diseases. In the U.S., the Orphan Drug Designation program confers Orphan Drug status to successful applicants for medicines intended for the ...
may be speedier for Orphan Drugs than those which do not receive Orphan Drug designation. About BXQ-350 In pre-clinical studies, Bexion’s first-in-class
Pharmaceuticals Receives Orphan Drug Designation for BXQ-350 for Malignant Glioma from FDA Bexion Pharmaceuticals Receives Orphan Drug Designation for BXQ-350 for ...
U.S. Food and Drug Administration (FDA) has granted the company Orphan Drug Designation for its proprietary drug, BXQ-350, for the treatment of malignant ...
Office of Orphan Drug Products Development reviews applications for Orphan Drug Designation to support development of medicines for underserved patient populations ...
FDA and a potentially faster regulatory process. “Receiving this orphan drug designation for BXQ-350 is another important milestone emerging from our innovative
Aerial BioPharma Aerial BioPharma, LLC
Access
- Technologies
- Core data such as location, employees, revenues
- Similar and peer companies
- and more
Web Quotes
Biopharma Receives FDA Orphan Drug Designation for Narcolepsy Drug in Development Aerial Biopharma Receives FDA Orphan Drug Designation for Narcolepsy Drug ...
molecules for conditions in the central nervous system, has received orphan drug designation for its narcolepsy drug in development. The U.S. Food and Drug
commercialize products that... Read More Aerial Biopharma Receives FDA Orphan Drug Designation for Narcolepsy Drug in Development News Follows Successful Phase ...
molecules for conditions in the central nervous system, has received orphan drug designation for its narcolepsy drug in development. The U.S. Food and Drug Administration
REGiMMUNE Corporation
Access
- Technologies
- Core data such as location, employees, revenues
- Similar and peer companies
- and more
Web Quotes
English RGI-2001 was granted Orphan Drug Designation from FDA Previous Next RGI-2001 was granted Orphan Drug Designation from FDA RGI-2001 has been granted ...
granted Orphan Drug Designation for RGI-2001 from FDA Tokyo, Japan-(OCT. 28, 2012) – REGiMMUNE Corporation announced today that RGI-2001, the company’s ...
company’s liposomal formulation of alpha-GalCer, has been granted Orphan Drug Designation by the U.S. Food & Drug Administration (FDA) for the treatment of Graft-versus-Host ...
(GvHD) associated with hematopoietic stem cell transplantation. Orphan Drug Designation is a special status granted by FDA to a novel product to treat a
English RGI-2001 was granted Orphan Drug Designation from FDA Previous Next RGI-2001 was granted Orphan Drug Designation from FDA Tokyo, Japan-(OCT. ...
company’s liposomal formulation of alpha-GalCer, has been granted Orphan Drug Designation by the U.S. Food & Drug Administration (FDA) for the treatment of ...
(GvHD) associated with hematopoietic stem cell transplantation. Orphan Drug Designation is a special status granted by FDA to a novel product to treat a
Midatech Pharma
Access
- Technologies
- Core data such as location, employees, revenues
- Similar and peer companies
- and more
Web Quotes
S. Food and Drug Administration ("FDA") has granted the Company orphan drug designation for MTX110 for the treatment of patients with Malignant Glioma, ...
adults. Commenting Craig Cook, CEO of Midatech said: "Receiving orphan drug designation for MTX110 is another important milestone to emerge from our innovative
Zytoprotec
Access
- Technologies
- Core data such as location, employees, revenues
- Similar and peer companies
- and more
Web Quotes
Press Release FDA Grants Orphan Drug Designation to Zytoprotec's Novel Dialysis Fluid Dialysis solution to improve outcomes of peritoneal dialysis Phase ...
the United States Food and Drug Administration (FDA) has granted orphan drug designation to PD-protec®, the Company's peritoneal dialysis fluid for the treatment ...
suffering from end-stage renal disease in Europe and the United States. Orphan drug designation is a special status granted by the FDA to treatments for rare diseases
- Patents - Contact/Imprint - News News 14.12.2017 FDA Grants Orphan Drug Designation to Zytoprotec's Novel Dialysis Fluid Pressemitteilung herunterladen
Topics
Search by any topicOnly spotfolio allows for searching with detailed technology terms, as we provide you with all topics that technology companies talk about.
Companies addressing these topics might be of specific interest to you, as they share more specific, niche topics.
- 1B-Clinical
- 1B-Study
- 1B-Trial
- 2A-Clinical
- 2A-Clinical-Trial
- 2A-Study
- Accompanying-Prospectus
- Advanced-Solid-Tumors
- Committee-Nominating
- Investigational-Medicine
- Investigational-Therapies
- Jefferies-Virtual
- Median-Duration
- Milestone-Payment
- Nasdaq-Listing
- Offering-Expenses
- Orphan-Drug-Status
- Patient-Dosed
- Pediatric-Disease
- Phase-1B-Clinical
- Received-Orphan
- Received-Orphan-Drug
- Receives-Orphan
- Registrational
- Therapy-Designation
- Treatment-Emergent
The following topics addressed by the majority of companies help you discover major players in the field.
- Biopharmaceutical-Company
- Biopharmaceutical-Company-Focused
- Breakthrough-Therapy
- Clinical-Stage
- Drug-Designation
- FDA-Orphan
- FDA-Orphan-Drug
- Fast-Track-Designation
- Forward-Looking-Statements
- Gemcitabine
- Granted-Orphan
- Granted-Orphan-Drug
- Oncology
- Ongoing-Phase
- Orphan-Designation
- Orphan-Drug
- Orphan-Drug-Designation
- Phase-1B
- Phase-II-Study
- Pivotal-Phase
- Product-Candidates
- Rare-Pediatric
- Rare-Pediatric-Disease
- Track-Designation
- Upcoming-Investor-Conferences
All companies in this field address the following more general topics.
- Biopharmaceutical
- Biotechnology
- Board
- Cell
- Chief
- Clinical
- Clinical-Development
- Clinical-Trials
- Company
- Development
- Disease
- Dose
- Dr
- Drug
- Efficacy
- FDA
- Forward-Looking
- Looking-Statements
- Medical
- Medicine
- Novel
- Orphan
- Patients
- Pharmaceutical
- Phase
- Pipeline
- Preclinical
- Research
- Scientific
- Study
- Therapeutics
- Therapies
- Treatment
- Trial
- University
Use Cases
Register nowTechnology scouting is the basis for your innovation management, identifies new technological developments as early as possible and protects you from disruptive business models.
Collect technology leaders, providers, start ups and potential new partners in lists via simple tagging to take further steps with your team.